Healthcare provider profile · identity verified

Alla Shteynman, MD

Internal Medicine · FLUSHING, NY · NPI 1386691517

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	747	266
Amlodipine Besylate	Amlodipine Besylate	645	218
Losartan Potassium	Losartan Potassium	504	172
Metoprolol Succinate	Metoprolol Succinate	328	112
Metformin Hcl	Metformin Hcl	303	92
Simvastatin	Simvastatin	295	90
Lisinopril	Lisinopril	246	76
Levothyroxine Sodium	Levothyroxine Sodium	203	68
Omeprazole	Omeprazole	192	71
Hydrochlorothiazide	Hydrochlorothiazide	169	65
Furosemide	Furosemide	130	53
Gabapentin	Gabapentin	127	50
Albuterol Sulfate Hfa	Albuterol Sulfate	125	32
Tamsulosin Hcl	Tamsulosin Hcl	124	44
Rosuvastatin Calcium	Rosuvastatin Calcium	123	46
Fluticasone Propionate	Fluticasone Propionate	116	48
Metoprolol Tartrate	Metoprolol Tartrate	116	34
Eliquis	Apixaban	111	38
Alendronate Sodium	Alendronate Sodium	96	34
Jardiance	Empagliflozin	96	37
Ibuprofen	Ibuprofen	89	50
Carvedilol	Carvedilol	86	30
Pantoprazole Sodium	Pantoprazole Sodium	80	26
Metformin Hcl Er	Metformin Hcl	75	25
Meclizine Hcl	Meclizine Hcl	69	28
Hydrocortisone	Hydrocortisone	67	32
Enalapril Maleate	Enalapril Maleate	66	17
Montelukast Sodium	Montelukast Sodium	66	23
Nifedipine Er	Nifedipine	65	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	59	20
Hydralazine Hcl	Hydralazine Hcl	59	22
Farxiga	Dapagliflozin Propanediol	58	16
Januvia	Sitagliptin Phosphate	57	19
Donepezil Hcl	Donepezil Hcl	51	18
Finasteride	Finasteride	51	19
Zolpidem Tartrate	Zolpidem Tartrate	51	18
Meloxicam	Meloxicam	50	28
Synthroid	Levothyroxine Sodium	49	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	47	37
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	43	15
Novolog Flexpen	Insulin Aspart	42	15
Alcohol Prep Pads	Alcohol Antiseptic Pads	37	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	36	12
Valsartan	Valsartan	36	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	35	11
Tresiba Flextouch U-100	Insulin Degludec	34	suppressed
Azithromycin	Azithromycin	33	30
Famotidine	Famotidine	33	16
Irbesartan	Irbesartan	33	suppressed
Atenolol	Atenolol	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	14
Ozempic	Semaglutide	32	11
Allopurinol	Allopurinol	30	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	30	suppressed
Sertraline Hcl	Sertraline Hcl	30	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	29	13
Fenofibrate	Fenofibrate Nanocrystallized	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Amoxicillin	Amoxicillin	27	26
Glipizide Er	Glipizide	27	suppressed
Indapamide	Indapamide	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Ezetimibe	Ezetimibe	26	14
Fosinopril Sodium	Fosinopril Sodium	24	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	24	23
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	22
Clotrimazole	Clotrimazole	22	11
Janumet	Sitagliptin Phos/Metformin Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Ibandronate Sodium	Ibandronate Sodium	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	18
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Single Use Swab	Alcohol Antiseptic Pads	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	13
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Naproxen	Naproxen	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	13	suppressed
Nadolol	Nadolol	13	suppressed
Digoxin	Digoxin	12	suppressed
Ibu	Ibuprofen	12	suppressed
Xalatan	Latanoprost	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Ciclopirox	Ciclopirox Olamine	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	11	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Glipizide	Glipizide	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Trazodone Hcl	Trazodone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error